Literature DB >> 9276022

Novel agonists of 5HT2C receptors. Synthesis and biological evaluation of substituted 2-(indol-1-yl)-1-methylethylamines and 2-(indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved therapeutics for obsessive compulsive disorder.

M Bös1, F Jenck, J R Martin, J L Moreau, A J Sleight, J Wichmann, U Widmer.   

Abstract

The syntheses of a series of substituted 2-(indol-1-yl)-1-methylethylamines and 2-(indeno[1,2- b]pyrrol-1-yl)-1-methylethylamines are reported. The binding affinities of the compounds at 5HT2C and 5HT2A receptors (79% homology in the transmembrane domain) were determined. The ligands displayed selectivity for 5HT2C receptors relative to 5HT2A receptors. Compounds were functionally characterized both in vitro and in vivo as 5HT2C receptor agonists. 5f, 5l, 5n, 5o, 5q, 14c, 14f, 14k, and 14m exhibited anticompulsive activity in an animal model of obsessive compulsive disorder.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9276022     DOI: 10.1021/jm970030l

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  13 in total

Review 1.  Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model.

Authors:  Clint E Canal; Drake Morgan
Journal:  Drug Test Anal       Date:  2012-04-19       Impact factor: 3.345

2.  Separate mechanisms for development and performance of compulsive checking in the quinpirole sensitization rat model of obsessive-compulsive disorder (OCD).

Authors:  Mark C Tucci; Anna Dvorkin-Gheva; Renee Sharma; Leena Taji; Paul Cheon; John Peel; Ashley Kirk; Henry Szechtman
Journal:  Psychopharmacology (Berl)       Date:  2014-02-28       Impact factor: 4.530

Review 3.  Pharmacological profile of the 5-HT(2C) receptor agonist WAY-163909; therapeutic potential in multiple indications.

Authors:  John Dunlop; Karen L Marquis; H K Lim; Louis Leung; John Kao; Cynthia Cheesman; Sharon Rosenzweig-Lipson
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

4.  Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes.

Authors:  David F Cummings; Diana C Canseco; Pratikkumar Sheth; James E Johnson; John A Schetz
Journal:  Bioorg Med Chem       Date:  2010-05-15       Impact factor: 3.641

5.  Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells.

Authors:  R H Porter; K R Benwell; H Lamb; C S Malcolm; N H Allen; D F Revell; D R Adams; M J Sheardown
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

6.  Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.

Authors:  Antony R Knight; Anil Misra; Kathleen Quirk; Karen Benwell; Dean Revell; Guy Kennett; Mike Bickerdike
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-07-30       Impact factor: 3.000

Review 7.  The use of lorcaserin in the management of obesity: a critical appraisal.

Authors:  Bo Bai; Yu Wang
Journal:  Drug Des Devel Ther       Date:  2010-12-20       Impact factor: 4.162

Review 8.  Innovative approaches for the development of antidepressant drugs: current and future strategies.

Authors:  Lee E Schechter; Robert H Ring; Chad E Beyer; Zoë A Hughes; Xavier Khawaja; Jessica E Malberg; Sharon Rosenzweig-Lipson
Journal:  NeuroRx       Date:  2005-10

9.  We Need 2C but Not 2B: Developing Serotonin 2C (5-HT2C) Receptor Agonists for the Treatment of CNS Disorders.

Authors:  Jianjun Cheng; Alan P Kozikowski
Journal:  ChemMedChem       Date:  2015-10-28       Impact factor: 3.466

10.  Indole-based allosteric inhibitors of HIV-1 integrase.

Authors:  Pratiq A Patel; Nina Kvaratskhelia; Yara Mansour; Janet Antwi; Lei Feng; Pratibha Koneru; Mathew J Kobe; Nivedita Jena; Guqin Shi; Mosaad S Mohamed; Chenglong Li; Jacques J Kessl; James R Fuchs
Journal:  Bioorg Med Chem Lett       Date:  2016-08-13       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.